Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.It is used off-label outside its FDA approval for Behçet's disease and other conditions. Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals. It cannot be given by mouth because the digestive system would destroy the drug.
英夫利昔單抗是一種嵌合單克隆抗體生物學藥物不利于腫瘤壞死因子-α (tumor necrosis factor-α，TNF-α) 用于治療自身免疫性疾病.英夫利昔單抗經美國食品和藥物管理局 (FDA) 治療克羅恩病，潰瘍性結腸炎，牛皮癬，銀屑病關節炎、強直性脊柱炎、類風濕關節炎.它是用于適應癥外 FDA 批準白塞病等情況.英夫利昔單抗是通過靜脈內輸注，通常在六到八周的間隔.它不能口服因為消化系統會摧毀.
采購中心
